Please assess the completion status of the following clinical trial:

Trial Title: The Use of Lumbar Erector Spinae Plane Block for Hip Arthroplasty at the L4 Interspace

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing primary hip arthroplasty~* American Society of Anesthesiologists (ASA) Category 1, 2, and 3~* Patients age ≥18 years~Exclusion Criteria:~* Patient refusal~* Inability to understand and sign consent~* Infection at the injection site~* Known allergy or hypersensitivity to ropivacaine or other amide local anesthetics~* Contraindication or patient refusal to get spinal anesthesia~* Thrombocytopenia (platelets \< 100,000)~* Coagulopathy (INR \> 1.4)~* Use of anticoagulant drugs that have not been discontinued in an appropriate amount of time before the surgery~* ASA Category 4 and 5

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Ultrasound-guided Erector Spinae Block (Type: None): Patients will then be randomized into one of the two groups above. One group will receive a lumbar erector spinae block at L4 with 30ml of 0.375% ropivacaine with 50 mcg of dexmedetomidine before the procedure using ultrasound guidance. The second group will receive no peripheral nerve block to serve as the control. All patients receiving nerve blocks will have a printed image of the block thus to confirm proper spread of local anesthetic both cranially and caudally.
- No Ultrasound-guided Erector Spinae Block (Type: None): Patients with no peripheral nerve block to serve as the control.

Based on this trial design, predict the completion outcome and termination type (if applicable).